Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intra-abdominal Infections
Conditions
Intra-abdominal Infections
Trial Timeline
Jun 1, 2012 → Aug 12, 2014
NCT ID
NCT01506271About Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam is a phase 2 stage product being developed by Merck for Intra-abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01506271. Target conditions include Intra-abdominal Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01506271 | Phase 2 | Completed |
Competing Products
20 competing products in Intra-abdominal Infections